Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New asthma drug TR4 enters first human tests

NCT ID NCT07272135

Disease control Sponsor: Trio Medicines Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tested a new drug called TR4 in 12 adults with mild-to-moderate asthma. TR4 is a beta-2 blocker, which works differently than typical asthma treatments. The main goal was to see if it is safe and tolerable, and to measure its effects on lung function and airway inflammation. Participants received either TR4 or a placebo, and researchers monitored their breathing and other health markers.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
TR4 (a beta-2 blocker drug)
What this could lead to
If it works, this could point toward a new way to control asthma by blocking certain receptors in the airways.
What could go wrong
This is a very early Phase 1 trial with only 12 people, so results may not apply to everyone. The drug may not improve asthma or could cause side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1

The first testing in people. Mainly checks safety and dose, usually in a small group.

Participants

12 people

The number who actually took part.

Started

Feb 2018

Finished

Aug 2022

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

21 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Men or women * Minimum 21 years old * History of mild-to-moderate asthma for at least 6 months and controlled by an inhaled SABA, as required * Otherwise healthy * Ideally have participated in previous asthma studies * No corticosteroid for whatever reason within 8 weeks of the start of dosing * No other prescription medicine within 28 days (apart from a short acting beta-agonist (SABA) or contraceptives in women) * No over-the-counter medicine within 7 days (apart from acetaminophen) before the start of dosing * Negative screen for drugs of abuse; forced expiratory volume in 1 second (FEV1) more than or equal to 70% predicted * Fractional exhaled nitric oxide (FeNO) more than or equal to 35 ppb * 15% fall in FEV1 after inhaled mannitol (PD15) * Non-smoker or past smoker (\<5 pack years) * Substitution of subject's SABA inhaler with an anti-cholinergic inhaler, ipratropium bromide, for use as a reliever or rescue medication during a run-in period and during dosing with TR4 or placebo. Exclusion Criteria: * Positive test for hepatitis B \& C or HIV * Drug or alcohol abuse * Airway infection or asthma exacerbation in the last 4 weeks * Current seasonal asthma * History of emergency treatment of asthma * Loss of more than 400 mL blood, or participation in other clinical trials of unlicensed medicines within the previous 3 months * Consumption of grapefruit or herbal remedies within the past 7 days * Objection by the subject's general practitioner (GP) * Subjects who are sexually active and not using reliable contraception * Women who are lactating, pregnant or plan to become pregnant during the study period * Positive polymerase chain reaction (PCR) test for SARS-CoV-2 virus * Subjects who have not received both doses of a COVID-19 vaccine.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Asthma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

asthma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Asthma

Contacts and locations

Locations

  • Hammersmith Medicines Research

    London, London, NW10 7EW, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.